One of the major functions of the COE is to build capacity for academic health centers and community-based organizations to collaborate in research, program delivery, evaluation and dissemination. To accomplish these functions, we rely on active Community Advisory Councils composed of key stakeholders representing the community agencies in the LCCC catchment area. The leading cancers in our catchment area are breast, prostate, colorectal, lung, pancreas, and liver and bile duct cancers. Behavioral and systemic risk factors linked to these cancers include obesity, physical inactivity, tobacco use, and limited access to cancer screening. Other issues include high prevalence of comorbidities such as metabolic syndrome, exposure to potentially carcinogenic environmental hazards, underutilization of genetic risk assessment and HPV vaccination, and health issues related to cancer survivorship. The disproportionate impact of these cancers and their risk factors on underserved minority populations, primarily Non-Latino Blacks (NLB) and Latinos (H/L), make cancer health disparities a major issue in our catchment area. COE leaders partner with basic/translational and clinical researchers to overcome barriers to access to cutting-edge clinical trial research that benefits all patients in the LCCC catchment areas.
The specific aims of community outreach and engagement (COE) are:
Aim 1 : Identify and assess the cancer burden and risk factors within the LCCC Consortium catchment area.
Aim 2 : Foster research that addresses the cancer burden in the LCCC Consortium catchment area with special emphasis on community-based research on vulnerable and underserved populations.
Aim 3 : Enhance and strengthen community-based partnerships and programs to deliver evidence-based cancer education and resources with impact within and beyond the LCCC Consortium catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-27
Application #
9924531
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
27
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications